Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin plus atorvastatin for high-risk calcific aortic valve disease with hyperlipidemia
ChiCTR2600135251Phase 4Not yet recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin in hyperlipidemia and aortic valve calcification (CAVD) (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoint: Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
hyperlipidemiaaortic valve calcification (CAVD)
Beyond the preview
Go deeper on ChiCTR2600135251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135251.